Clinical Trials Browser

Phase 1/2 × Non-small Cell Lung Cancer Metastatic × MLN 8237 × Clear all

NCT01471964 2018-05-17

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Phase 1/2 Terminated

Non-small Cell Lung Cancer Metastatic